Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in N2 positive NSCLC after neoadjuvant CCRT and surgery
NCT03053856Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Feb 2017
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Primary endpoint: Disease-Free Survival at 24 months. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03053856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053856.